AveXis, Inc. (NASDAQ:AVXS)‘s stock had its “hold” rating reiterated by analysts at Royal Bank Of Canada in a report released on Thursday, November 2nd. They presently have a $92.00 price objective on the stock. Royal Bank Of Canada’s price target would indicate a potential downside of 4.16% from the company’s previous close.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Sanford C. Bernstein began coverage on shares of AveXis in a research note on Thursday, July 27th. They set an “outperform” rating and a $108.00 target price for the company. Morgan Stanley began coverage on shares of AveXis in a research note on Thursday, August 3rd. They set an “overweight” rating and a $118.00 target price for the company. BMO Capital Markets reissued a “buy” rating and set a $123.00 target price on shares of AveXis in a research note on Friday, August 11th. Finally, Chardan Capital reissued a “buy” rating and set a $130.00 target price (up previously from $102.50) on shares of AveXis in a research note on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $110.67.
AveXis (NASDAQ AVXS) opened at $95.99 on Thursday. AveXis has a 1-year low of $44.68 and a 1-year high of $108.27.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the business posted ($0.87) EPS. equities analysts anticipate that AveXis will post -6.23 earnings per share for the current fiscal year.
In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the sale, the vice president now owns 1,780 shares in the company, valued at $165,985. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,340 shares of company stock worth $3,559,683. Company insiders own 18.60% of the company’s stock.
Several large investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of AveXis by 13.1% in the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares during the last quarter. BlackRock Inc. grew its position in shares of AveXis by 34.7% in the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AveXis by 31.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after buying an additional 352,456 shares during the last quarter. Finally, State Street Corp grew its position in shares of AveXis by 104.2% in the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after buying an additional 510,189 shares during the last quarter. 94.90% of the stock is currently owned by institutional investors.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with our FREE daily email newsletter.